Sanovus - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 1,260,590 | 1,506,234 | 2,220,626 | 2,048,317 | 2,039,682 | 2,309,306 | 2,636,040 | 3,097,806 |
| Profit before tax | 38,601 | 112,525 | 316,881 | 123,375 | 110,327 | 249,545 | 124,613 | 271,215 |
| Net profit | 29,625 | 93,470 | 268,585 | 104,452 | 92,326 | 208,249 | 100,837 | 219,526 |
| Equity | 282,829 | 326,275 | 594,860 | 579,312 | 571,638 | 659,887 | 640,724 | 740,250 |
| Liabilities | 300,465 | 308,768 | 371,729 | 437,119 | 411,605 | 382,404 | 605,079 | 597,677 |
| Non-current assets | 119,449 | 95,916 | 171,962 | 138,653 | 103,545 | 98,802 | 165,964 | 129,078 |
| Current assets | 460,802 | 534,252 | 784,145 | 866,784 | 869,163 | 923,641 | 1,057,382 | 1,191,735 |
| Total assets | 580,251 | 630,168 | 956,107 | 1,005,437 | 972,708 | 1,022,443 | 1,223,346 | 1,320,813 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 430,747 | 550,291 | 608,674 |
| Social insurance contributions | - | - | - | - | - | 92,246 | 116,933 | 134,332 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +11.6% | +19.5% | +47.4% | -7.8% | -0.4% | +13.2% | +14.1% | +17.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 5.1% | 14.8% | 28.1% | 10.4% | 9.5% | 20.4% | 8.2% | 16.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 10.5% | 28.6% | 45.2% | 18.0% | 16.2% | 31.6% | 15.7% | 29.7% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 2.4% | 6.2% | 12.1% | 5.1% | 4.5% | 9.0% | 3.8% | 7.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 3.1% | 7.5% | 14.3% | 6.0% | 5.4% | 10.8% | 4.7% | 8.8% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.1 | 0.9 | 0.6 | 0.8 | 0.7 | 0.6 | 0.9 | 0.8 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 83,575 | 93,652 | 141,742 | 139,658 | 155,900 | 171,060 | 181,796 | 212,421 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Sanovus - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2022-12-16 | 2022-12-18 | 520.48 |
Sanovus - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Sanovus, UAB (code 222222030) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €3.10M, up 17.5% year on year and 34.1% over two years. Net profit reached €219.5K, compared with €100.8K in 2024 and €208.2K in 2023, showing a recovery after a weaker 2024 result. Profit margin improved to 7.1% in 2025 from 3.8% in 2024, though it remained below the 9.0% level seen in 2023. The balance sheet also expanded: total assets increased to €1.32M, equity rose to €740.2K, and liabilities stood at €597.7K. The equity ratio was 56.0% and debt to equity was 0.81, indicating a moderate leverage profile. Return on equity was 29.7% and return on assets 16.6%, supported by an asset turnover of 2.35x. Revenue per employee was €221.3K, while profit per employee was €15.7K, suggesting solid operating productivity in 2025.